HRTS
Cardiovascular and Metabolic ETF

Addressing the metabolic and heart disease epidemic

Why HRTS ETF?

icons-themes-hrts-underpenetrated
Underpenetrated, large market

Obesity is forecast to affect one in four people globally by 2035, and obesity-related conditions like diabetes and heart disease represent vast markets with significant growth potential.

Source: World Obesity Atlas, March 2023.
icons-themes-hrts-innovation
Innovation

The Industry is witnessing significant progress in obesity therapeutics led by new drugs such as Ozempic and Wegovy, as well as a renaissance in cardiovascular therapies through novel platforms like gene editing.

icons-themes-hrts-research
Research expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations.

icons-themes-hrts-barriers
Barriers to entry

In our view, many of the businesses identified have high barriers to entry, such as such as costly and lengthy clinical trials, large salesforce requirements in primary care markets, and substantial patent protection.

icons-themes-oncology-uncorrelated
Uncorrelated

Performance of many companies relies on clinical or commercial success, which is an uncorrelated source of return.

Fund Overview

Fund Details

As of February 20, 2024
Primary Exchange
Nasdaq
Ticker
HRTS
AuM (USD)
$39,095,931
# of Holdings
43
Fund Inception Date
11/20/23
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
Implied Liquidity (# of shares)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
1,261,780
Implied Liquidity (USD)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
$41M
Shares Outstanding
1,200,000
Investment Advisor
Tema Global Limited
Sub-Investment Advisor
NEOS Investments, LLC
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/30/2025.

Fund Summary

The actively managed Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools.

The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.

Source: Our World in Data, November 2023.

Portfolio Manager

David K. Song, MD, PhD, CFA
Investment Partner
David K. Song, MD, PhD, CFA
David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.

How does the Tema HRTS ETF fit in a portfolio?

Investment Style Box

Frame 48095809

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM
Ellipse 625

HRTS ETF

Ellipse 625

Equity core

Where could a position be funded from?

  • Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
  • Provides a balanced exposure across key technologies and company risk profiles.
  • Could replace a satellite or a growth-oriented position.

Portfolio Breakdown

Top 10 holdings

As of February 20, 2024
Company
% of Nav
ELI LILLY & CO.
5.10%
VERTEX PHARMACEUTICALS, INC.
5.03%
NOVO NORDISK A/S
4.92%
AMGEN, INC.
4.45%
DEXCOM, INC.
3.36%
CHUGAI PHARMACEUTICAL CO., LTD.
3.12%
CYTOKINETICS, INC.
3.06%
ASCENDIS PHARMA A/S
2.98%
MEDTRONIC PLC
2.95%
INSULET CORP.
2.89%

Country Breakdown

United States
76.89%
Denmark
9.64%
Japan
3.12%
Ireland
2.95%
Others
7.40%

Industry Breakdown

Healthcare
98.90%
Cash & Cash Equivalents
1.09%
  • Performance
  • Distributions
  • Premium / Discount

Prices & Performance

As of
Jan 31, 2024

HRTS

3 months

1 Year

3 Years

5 Years

Since inception

NAV
17.56% 15.18%
Market Price
18.15% 15.64%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.


The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

ST Cap Gains

0.18 -0.14 0.11 0.68 0.31 0.41 0.35 0.27 0.06 0.33 0.25 0.45 0.04

Premium/Discount

Сhart Table

HRTS NAV / Market Price

NAV$32.58
NAV change (1D)($0.37)
Median Bid/Ask Spread (30 Day)0.37%
Market Price$32.64
Market Price Change (1D)($0.27)
Premium/Discount0.18%
As of: February 20, 2024

How to buy

*Neither Tema Global Limited nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.